Ablacon (Menlo Park, Calif.) announced this week that it has secured a $10 million venture debt facility from Western Technology Investment (WTI), accompanied by a $2 million equity investment.
The money will help fund the first multicenter randomized clinical trial for Ablamap, Ablacon’s mapping system to guide the treatment of people with atrial fibrillation.
“WTI has been a trusted investment partner in several of my former companies, and I am delighted to welcome them into Ablacon,” Ablacon CEO Duke Rohlen said in a July 23 news release.
The investment comes nearly three months after a $21.5 million Series A investment led by Ajax Health.
DeviceTalks Minnesota's leadership track is designed to provide attendees with insights on topics such as:
Use code SAVE15 to save 15%!